BIOTECHNOLOGY

articles with this tag

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

Dec 19, 2019

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

Get email alerts as soon as new articles are released.

Thanks for subscribing!

X